Purchase this article with an account.
Peter Henry Scanlon, Irene Stratton, Clare Bailey, Haralobos Eleftheriadis, Naren Dhingra, James S Talks, Tunde Peto; Audit of anti-VEGF injections for diabetic macula edema in 21 UK hospitals. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3607. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To characterise demographic data and clinical data for patients with diabetic macula edema DME in 21 UK centres
Electronic patient records were extracted in August 2017. The first treated eyes of 1937 people with DME treated with either or both of aflibercept and ranibizumab included. Descriptive statistics for baseline characteristics were derived.
Of those included 764 (39%) were women. Of those first treated before August 2016 74% had follow-up data at 12 months. Median results at first injection (25th to 75th centile) were: age 65 years (56-74), Best Measured Visual Acuity (BMVA) 6/19 (6/12 to 6/30) (Snellen), Index Multiple Deprivation scores 20 (11 to 34). Type of diabetes was recorded in 1489 (77%), of these 1273 (85.5%) had Type 2 diabetes. The median number of injections in those followed for 12 months was 7 (5 to 8). For those with BMVA at baseline and at 12 months median improvement was 6 letters (0 to 13).There was significant heterogeneity between centres, median age at first injection ranging from 61 to 72 years, BMVA 6/12 to 6/30, the proportion with data available at 12 months 68% to 85%, median number of injections in first year 6 to 8, median improvement over 12 months 0 to 11 letters.
Age, baseline VA, number of injections and variable follow-up should be considered when comparing visual outcomes between centres.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only